Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 11/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | BCR | P11274 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286451 | 0.89 | CDK5 (0.45) | CDK5ROCK1KDRRETFLT1 | |
| SCHEMBL4279389 | 0.89 | PTK2 (0.46) | CDK5ROCK1KDRRETFLT1 | |
| SCHEMBL4279521 | 0.88 | KDR (0.41) | CDK5ROCK1KDRRETFLT1 | |
| SCHEMBL4287054 | 0.88 | KDR (0.44) | CDK5KDRRETFLT1PDGFRA | |
| SCHEMBL4279382 | 0.86 | KDR (0.45) | CDK5KDRRETFLT1PDGFRA | |
| SCHEMBL4279410 | 0.86 | MET (0.45) | CDK5KDRRETFLT1PDGFRA | |
| SCHEMBL4284798 | 0.86 | CDK5 (0.46) | CDK5KDRRETFLT1PDGFRA | |
| SCHEMBL4285064 | 0.85 | KDR (0.46) | CDK5KDRRETFLT1ABL1 | |
| SCHEMBL4287061 | 0.85 | CDK5 (0.42) | CDK5KDRRETFLT1PDGFRA | |
| SCHEMBL4282680 | 0.85 | CDK5 (0.42) | CDK5KDRRETFLT1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | claimed |
| EP-1934200-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-06-25 | — | — | EP | claimed |
| WO-2007035309-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1934200-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007035309-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035309-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | ABL1, MET, ERBB2 | CDK5 113/4885ROCK1 221/4885KDR 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.